Villavicencio

Researchers are evaluating the effect of tozorakimab, added to standard care, in adults hospitalized with viral lung infection who need supplemental oxygen. The study focuses on preventing death or progression to invasive mechanical ventilation or extracorporeal membrane oxygenation by day 28. This is a Phase III, multicenter, randomized, double-blind trial comparing tozorakimab to placebo in patients with viral lung infection causing acute respiratory failure. Participants will receive a single intravenous dose of either tozorakimab or a matching placebo on the first day of the study. Both groups continue to receive standard care for their viral lung infection. The study is designed to assess the safety and efficacy of tozorakimab as an add-on therapy in this patient population. Throughout the study, researchers will monitor participants for survival and the need for invasive mechanical ventilation or ECMO up to 28 days after treatment. The main outcome measured is the proportion of patients who die or require mechanical ventilation or ECMO by day 28. Participants will be closely observed during hospitalization, with data collected on their respiratory status and treatment outcomes to evaluate the study drug's impact and safety.

This research aims to describe and evaluate stroke events in a hospital located in the Orinoco region of Colombia. It involves reviewing a database created from routinely uploaded patient information related to stroke cases. The goal is to recognize patterns of care, identify delays in treatment, and assess adherence to clinical guidelines, helping to improve healthcare quality and standardize treatment strategies for stroke patients. The study collects demographic, disease, and discharge outcome data from a stroke registry in a high-median-complexity hospital. These records are systematically gathered in the RES-Q database and analyzed using statistical methods to present frequency and proportion of various factors. This cross-sectional trial provides insight into stroke care in a region where such data is scarce. Participants' information is reviewed monthly by a scientific committee to monitor functional condition outcomes 30 days after stroke events. The study focuses on improving healthcare quality through ongoing evaluation of stroke management. Participant involvement includes data collection from medical records, imaging results, and clinical diagnosis, with no active intervention or treatment administered as part of the study.